Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Raab

Showing results (361-370 of 427) with videos related to

Pageof 43
Sort By:
Blood|June 12, 2025
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRSTMaximilian Merz, Nico Gagelmann, Samih Smaili, et al.
Cardio-Oncology (London, England)|July 4, 2025
Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trialLisa B Leypoldt, Linlin Guo, Britta Besemer, et al.
Leukemia|May 15, 2025
Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibodyMarc S Raab, Yael C Cohen, Fredrik Schjesvold, et al.
Haematologica|September 28, 2019
IKZF1/3 and CRL4<sup>CRBN</sup> E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myelomaSantiago Barrio, Umair Munawar, Yuan Xiao Zhu, et al.
Science Immunology|May 3, 2024
The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillanceMichael Kilian, Mirco J Friedrich, Kevin Hai-Ning Lu, et al.
Leukemia|March 20, 2015
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myelomaE K Mai, U Bertsch, J Dürig, et al.
Leukemia|April 6, 2023
Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibodyMarc S Raab, Yael C Cohen, Fredrik Schjesvold, et al.
Leukemia|December 22, 2025
Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed/refractory multiple myelomaMartin Grözinger, Muriel Schlanke, Jana Gröne, et al.
Blood Cancer Discovery|May 22, 2025
Mutagenic impact and evolutionary influence of chemo-radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Blood Cancer Discovery|February 13, 2026
Clinical scores to predict toxicities and outcomes in patients with multiple myeloma undergoing bispecific T-cell engager therapyJan H Frenking, Christine Riedhammer, Thomas Hielscher, et al.
Pageof 43

Showing results (361-370 of 427) with videos related to

Sort By:
Pageof 43
Blood|June 12, 2025
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRSTMaximilian Merz, Nico Gagelmann, Samih Smaili, et al.
Cardio-Oncology (London, England)|July 4, 2025
Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trialLisa B Leypoldt, Linlin Guo, Britta Besemer, et al.
Leukemia|May 15, 2025
Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibodyMarc S Raab, Yael C Cohen, Fredrik Schjesvold, et al.
Haematologica|September 28, 2019
IKZF1/3 and CRL4<sup>CRBN</sup> E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myelomaSantiago Barrio, Umair Munawar, Yuan Xiao Zhu, et al.
Science Immunology|May 3, 2024
The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillanceMichael Kilian, Mirco J Friedrich, Kevin Hai-Ning Lu, et al.
Leukemia|March 20, 2015
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myelomaE K Mai, U Bertsch, J Dürig, et al.
Leukemia|April 6, 2023
Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibodyMarc S Raab, Yael C Cohen, Fredrik Schjesvold, et al.
Leukemia|December 22, 2025
Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed/refractory multiple myelomaMartin Grözinger, Muriel Schlanke, Jana Gröne, et al.
Blood Cancer Discovery|May 22, 2025
Mutagenic impact and evolutionary influence of chemo-radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Blood Cancer Discovery|February 13, 2026
Clinical scores to predict toxicities and outcomes in patients with multiple myeloma undergoing bispecific T-cell engager therapyJan H Frenking, Christine Riedhammer, Thomas Hielscher, et al.
Pageof 43